Previous 10 | Next 10 |
Atossa Genetics (NASDAQ: ATOS ) has signed a contract with Stockholm South General Hospital in Sweden to conduct a Phase 2 study of Atossa’s oral Endoxifen to reduce mammographic breast density (MBD) in women. More news on: Atossa Genetics Inc., Healthcare stocks news, Read mo...
SEATTLE, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it has contracted with Stockholm South Gener...
SEATTLE, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO, will be a featured presenter...
Atossa Genetics (NASDAQ: ATOS ): Q3 GAAP EPS of -$0.36 beats by $0.16 . More news on: Atossa Genetics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SEATTLE, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial results for the third quarter ended Sep...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch to s...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SEATTLE, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO and General Counsel of Atossa...
Viveve Medical (NASDAQ: VIVE ) +109% on robust volume on no particular news. More news on: Viveve Medical, Inc., Achillion Pharmaceuticals, Inc., Ideal Power Inc., Stocks on the move, Read more ...
SEATTLE and ENCINO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, and The Dr. Susan Love Research Foundation, an...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...